Skip to main content
Erschienen in: Pediatric Cardiology 8/2013

01.12.2013 | Original Article

Amiodarone Monitoring Practices in Pediatric Hospitals in the United States

verfasst von: Brady S. Moffett, Santiago O. Valdes, Jeffrey J. Kim

Erschienen in: Pediatric Cardiology | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Laboratory monitoring of amiodarone therapy is recommended due to the high incidence of adverse events associated with the drug. The use of appropriate monitoring is unknown at pediatric hospitals. The Pediatric Health Information System database was queried during a 5-year period for all patients who received amiodarone while hospitalized. Use of thyroid function testing, hepatic function testing, electrocardiogram, pulmonary function testing, and chest X-ray for patients was identified. Incidence of individual monitoring tests and complete monitoring profile was identified and compared across patient demographic and clinical factors and pediatric hospital. A total of 1,703 patients met the study criteria, and the incidence of complete amiodarone monitoring for all patients was 7.6 %. The least common monitoring test performed was triiodothyronine at 19.4 %, and the most common was electrocardiogram at 89.7 %. Critically ill patients and neonates were more likely to have amiodarone monitoring. Considerable variation in monitoring practices between pediatric hospitals was identified. Monitoring of amiodarone therapy in patients admitted to pediatric hospitals is low. Future efforts to standardize care are warranted.
Literatur
1.
Zurück zum Zitat Ardura J, Hermoso F, Bermejo J (1988) Effect on growth of children with cardiac dysrhythmias treated with amiodarone. Pediatr Cardiol 9(1):33–36CrossRefPubMed Ardura J, Hermoso F, Bermejo J (1988) Effect on growth of children with cardiac dysrhythmias treated with amiodarone. Pediatr Cardiol 9(1):33–36CrossRefPubMed
2.
Zurück zum Zitat Birmingham WP (1998) More on an infant with acute pulmonary toxicity during amiodarone therapy. Am J Cardiol 81(9):1171CrossRefPubMed Birmingham WP (1998) More on an infant with acute pulmonary toxicity during amiodarone therapy. Am J Cardiol 81(9):1171CrossRefPubMed
3.
Zurück zum Zitat Bowers PN, Fields J, Schwartz D, Rosenfeld LE, Nehgme R (1998) Amiodarone induced pulmonary fibrosis in infancy. Pacing Clin Electrophysiol 21(8):1665–1667CrossRefPubMed Bowers PN, Fields J, Schwartz D, Rosenfeld LE, Nehgme R (1998) Amiodarone induced pulmonary fibrosis in infancy. Pacing Clin Electrophysiol 21(8):1665–1667CrossRefPubMed
4.
Zurück zum Zitat Costigan DC, Holland FJ, Daneman D, Hesslein PS, Vogel M, Ellis G (1986) Amiodarone therapy effects on childhood thyroid function. Pediatrics 77(5):703–708PubMed Costigan DC, Holland FJ, Daneman D, Hesslein PS, Vogel M, Ellis G (1986) Amiodarone therapy effects on childhood thyroid function. Pediatrics 77(5):703–708PubMed
5.
Zurück zum Zitat Coumel P, Lucet V, Do ND (1983) The use of amiodarone in children. Pacing Clin Electrophysiol 6(5 Pt 1):930–939CrossRefPubMed Coumel P, Lucet V, Do ND (1983) The use of amiodarone in children. Pacing Clin Electrophysiol 6(5 Pt 1):930–939CrossRefPubMed
6.
Zurück zum Zitat Flach AJ, Dolan B, Sudduth B (1984) The use of amiodarone in children. Pacing Clin Electrophysiol 7(6 Pt 1):1086–1087CrossRefPubMed Flach AJ, Dolan B, Sudduth B (1984) The use of amiodarone in children. Pacing Clin Electrophysiol 7(6 Pt 1):1086–1087CrossRefPubMed
7.
Zurück zum Zitat Goldschlager N, Epstein AE, Naccarelli GV et al (2007) A practical guide for clinicians who treat patients with amiodarone. Heart Rhythm 4(9):1250–1259CrossRefPubMed Goldschlager N, Epstein AE, Naccarelli GV et al (2007) A practical guide for clinicians who treat patients with amiodarone. Heart Rhythm 4(9):1250–1259CrossRefPubMed
8.
Zurück zum Zitat Hacihamdioglu B, Berberoglu M, Siklar Z et al (2010) Amiodarone-induced thyrotoxicosis in children and adolescents is a possible outcome in patients with low iodine intake. J Pediatr Endocrinol Metab 23(4):363–368CrossRefPubMed Hacihamdioglu B, Berberoglu M, Siklar Z et al (2010) Amiodarone-induced thyrotoxicosis in children and adolescents is a possible outcome in patients with low iodine intake. J Pediatr Endocrinol Metab 23(4):363–368CrossRefPubMed
9.
Zurück zum Zitat Kannan R, Yabek SM, Garson A Jr, Miller S, McVey P, Singh BN (1987) Amiodarone efficacy in a young population: relationship to serum amiodarone and desethylamiodarone levels. Am Heart J 114(2):283–287CrossRefPubMed Kannan R, Yabek SM, Garson A Jr, Miller S, McVey P, Singh BN (1987) Amiodarone efficacy in a young population: relationship to serum amiodarone and desethylamiodarone levels. Am Heart J 114(2):283–287CrossRefPubMed
10.
Zurück zum Zitat Labombarda F, Ou P, Stos B, de Blic J, Villain E, Sidi D (2008) Acute amiodarone-induced pulmonary toxicity: An association of risk factors in a child operated by arterial switch operation. Congenit Heart Dis 3(5):365–367CrossRefPubMed Labombarda F, Ou P, Stos B, de Blic J, Villain E, Sidi D (2008) Acute amiodarone-induced pulmonary toxicity: An association of risk factors in a child operated by arterial switch operation. Congenit Heart Dis 3(5):365–367CrossRefPubMed
11.
Zurück zum Zitat Lomenick JP, Jackson WA, Backeljauw PF (2004) Amiodarone-induced neonatal hypothyroidism: a unique form of transient early-onset hypothyroidism. J Perinatol 24(6):397–399CrossRefPubMed Lomenick JP, Jackson WA, Backeljauw PF (2004) Amiodarone-induced neonatal hypothyroidism: a unique form of transient early-onset hypothyroidism. J Perinatol 24(6):397–399CrossRefPubMed
12.
Zurück zum Zitat Niinikoski H, Hamalainen AM, Ekblad H, Soukka H (2007) Neonatal hypothyroidism after amiodarone therapy. Acta Paediatr 96(5):773–774CrossRefPubMed Niinikoski H, Hamalainen AM, Ekblad H, Soukka H (2007) Neonatal hypothyroidism after amiodarone therapy. Acta Paediatr 96(5):773–774CrossRefPubMed
13.
Zurück zum Zitat Shuler CO, Case CL, Gillette PC (1993) Efficacy and safety of amiodarone in infants. Am Heart J 125(5 Pt 1):1430–1432CrossRefPubMed Shuler CO, Case CL, Gillette PC (1993) Efficacy and safety of amiodarone in infants. Am Heart J 125(5 Pt 1):1430–1432CrossRefPubMed
14.
Zurück zum Zitat Trudel K, Sanatani S, Panagiotopoulos C (2011) Severe amiodarone-induced hypothyroidism in an infant. Pediatr Crit Care Med 12(1):e43–e45CrossRefPubMed Trudel K, Sanatani S, Panagiotopoulos C (2011) Severe amiodarone-induced hypothyroidism in an infant. Pediatr Crit Care Med 12(1):e43–e45CrossRefPubMed
15.
Zurück zum Zitat Vrobel TR, Miller PE, Mostow ND, Rakita L (1989) A general overview of amiodarone toxicity: its prevention, detection, and management. Prog Cardiovasc Dis 31(6):393–426CrossRefPubMed Vrobel TR, Miller PE, Mostow ND, Rakita L (1989) A general overview of amiodarone toxicity: its prevention, detection, and management. Prog Cardiovasc Dis 31(6):393–426CrossRefPubMed
16.
Zurück zum Zitat Wong KK, Potts JE, Etheridge SP, Sanatani S (2006) Medications used to manage supraventricular tachycardia in the infant a North American survey. Pediatr Cardiol 27(2):199–203CrossRefPubMed Wong KK, Potts JE, Etheridge SP, Sanatani S (2006) Medications used to manage supraventricular tachycardia in the infant a North American survey. Pediatr Cardiol 27(2):199–203CrossRefPubMed
Metadaten
Titel
Amiodarone Monitoring Practices in Pediatric Hospitals in the United States
verfasst von
Brady S. Moffett
Santiago O. Valdes
Jeffrey J. Kim
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 8/2013
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-013-0710-8

Weitere Artikel der Ausgabe 8/2013

Pediatric Cardiology 8/2013 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.